Search Results

You are looking at 61 - 70 of 2,687 items for :

  • Refine by Access: Content accessible to Me x
Clear All
Full access

Therapeutic Advances in Relapsed or Refractory Multiple Myeloma

Kenneth C. Anderson

disease. Durie BGM. Concise Review of the Disease and Treatment Options; Multiple Myeloma, Cancer of the Bone Marrow. 2011/2012 ed. International Myeloma Foundation; North Hollywood, CA. Available at http://myeloma.org/pdfs/CR2011-Eng_b1.pdf . Accessed

Full access

CLO22-036: The Role of Zoledronic Acid Administration Among Lymphoma Patients Receiving Chemotherapy: A Systematic Review

Jacqueline Agustin, Flordeluna Mesina, and Eryll Sy

than English, review papers, or on-going clinical trials. The eligible studies were reviewed in full-text independently by two authors. Methodological quality and risk of bias assessment were done. The findings from the individual studies were

Full access

HSR20-090: Current Utilization of Genomic Testing and Barriers to Optimal Patient Care: A Targeted Literature Review

Allysen Kaminski, Jyoti Aggarwal, and Gboyega Adeboyeje

Objectives: Targeted therapy offers potential improvements in treatment costs and quality, yet its success hinges on the ability to accurately identify biomarker targets and ensure access to testing. This review aimed to understand global barriers

Full access

EPR24-109: Intentional Weight Loss and Associated Cancer Incidence Among Patients With Overweight or Obesity: A Systematic Literature Review

Chi-Yin Liao, Kristin M. Sheffield, Meredith M. Hoog, David Schapiro, Raghuvir Keni, Wambui Grace Gathirua-Mwangi, and Hong Kan

systematic literature review (SLR) was conducted to assess the association between intentional weight loss and cancer incidence, inclusive of all cancers and 13 obesity-associated cancers, from recent observational studies and clinical trials. Methods: A

Full access

HSR22-142: A Review of Lung Cancer Screening Compliance in a Federally Qualified Health Center: Uncovering Unconscious Bias

Janeen Grant-Sittol, Rani Sittol, Latoya Gayle, Sharde Mcleish, Jodi-Ann Smith, Jason Lofters, Zachary Banbury, Natasha Rastogi, and Tanganyika Barnes

center, retrospective observational study was done of patients seen at the Englewood NHCAC from January 1, 2020 to December 31, 2020. Chart review was performed using a checklist to assess adherence to 2013 screening guidelines. Comparisons were analyzed

Full access

CLO24-069: Pneumonitis Incidences in Metastatic Non–Small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-Analysis

Sakditad Saowapa, Natchaya Polpichai, Pharit Siladech, Chalothorn Wannaphut, Manasawee Tanariyakul, Phuuwadith Wattanachayakul, and Pakin Lalitnithi

immunotherapy. Immunotherapy (checkpoint inhibitors utilization) boosts the immune system to recognize and destroy cancer cells. However, it is often associated with immune-related complications such as pneumonitis. Objective: The present review aims to

Full access

Gleason Scoring at a Comprehensive Cancer Center: What’s The Difference?

Natasha C. Townsend, Karen Ruth, Tahseen Al-Saleem, Eric M. Horwitz, Mark Sobczak, Robert G. Uzzo, Rosalia Viterbo, and Mark K. Buyyounouski

have been made regarding the need for a second confirmatory pathology review (SPR) before beginning treatment. Furthermore, no reported series have examined the impact of an SPR for men receiving external-beam radiotherapy. Of the 2 series that examine

Full access

Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review

Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea

Primary malignant melanoma of the pineal gland is a rare disease entity, with only 24 cases reported in the literature to date. 1 Given the rarity of this malignancy, management is primarily based on case reports and literature reviews. We present

Full access

EPR23-077: Incidence and Mechanisms of Coexisting Hematological Malignancies: Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia—A Retrospective Review

Sujan Badal and Mariam Alamgir

of these two distinct hematological neoplasms have been reported in published literature, although the incidence and underlying pathogenetic mechanism of this phenomenon remains unclear. Methods: A retrospective review was performed on 47 screened

Full access

Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence

Gary H. Lyman

The prophylactic use of myeloid growth factors reduces the risk of chemotherapy-induced neutropenia and its complications, including febrile neutropenia and infection-related mortality. Perhaps most importantly, the prophylactic use of colony-stimulating factors (CSFs) has been shown to reduce the need for chemotherapy dose reductions and delays that may limit chemotherapy dose intensity, thereby increasing the potential for prolonged disease-free and overall survival in the curative setting. National surveys have shown that the majority of patients with potentially curable breast cancer or non-Hodgkin's lymphoma (NHL) do not receive prophylactic CSF support. In this issue, the National Comprehensive Cancer Network presents guidelines for the use of myeloid growth factors in patients with cancer. These guidelines recommend a balanced clinical evaluation of the potential benefits and harms associated with chemotherapy to define the treatment intention, followed by a careful assessment of the individual patient's risk for febrile neutropenia and its complications. The decision to use prophylactic CSFs is then based on the patient's risk and potential benefit from such treatment. The routine prophylactic use of CSFs in patients receiving systemic chemotherapy is recommended in patients at high risk (>20%) of developing febrile neutropenia or related complications that may compromise treatment. Where compelling clinical indications are absent, the potential for CSF prophylaxis to reduce or offset costs by preventing hospitalization for FN should be considered. The clinical, economic, and quality of life data in support of these recommendations are reviewed, and important areas of ongoing research are highlighted.